ERBB2 and neoplasm: As an antibody-drug conjugate (ADC), T-DXd combines a monoclonal antibody targeting HER2 with a potent cytotoxic payload, enabling highly specific delivery of chemotherapy to HER2-expressing tumor cells, thereby overcoming several limitations associated with traditional HER2-directed therapies (Trail et al., 2018).